Related Experiment Videos
5 alpha-reductase inhibitors and prostatic disease
1Department of Urology, Erasmus University, Rotterdam, The Netherlands.
Clinical Endocrinology
|August 1, 1994
Summary
5 alpha-Reductase inhibitors offer targeted treatments for conditions like male pattern baldness and prostate issues. These compounds effectively reduce dihydrotestosterone (DHT) levels, leading to therapeutic benefits in various tissues.
Area of Science:
- Pharmacology
- Biochemistry
- Dermatology
- Urology
Background:
- 5 alpha-Reductase (5α-R) inhibitors represent a novel class of therapeutic agents.
- These inhibitors specifically target type I and type II 5α-R enzymes.
- Potential applications include skin conditions and prostate diseases.
Purpose of the Study:
- To explore the therapeutic potential of 5α-R inhibitors.
- To investigate the effects of these inhibitors on dihydrotestosterone (DHT) and testosterone levels.
- To evaluate their efficacy in treating conditions like benign prostatic hyperplasia (BPH).
Main Methods:
- Cloning of cDNA for type I and type II 5α-R enzymes.
- Administration of orally effective 4-azasteroids as 5α-R inhibitors.
- Measurement of plasma and tissue levels of DHT and testosterone in various species and human subjects.
Main Results:
- 5α-R inhibitors decreased plasma DHT by approximately 65% and tissue DHT by up to 85% in specific organs.
- A slight increase in plasma testosterone and a reciprocal rise in tissue testosterone were observed.
- Type II 5α-R inhibitors induced a ~30% shrinkage in BPH in men and similar effects in rats.
Conclusions:
- 5α-R inhibitors demonstrate significant efficacy in reducing DHT levels.
- These compounds show promise for treating androgen-dependent conditions, including BPH and certain skin disorders.
- Further research may elucidate optimal therapeutic strategies utilizing 5α-R inhibition.